ArticleRMD open2026
Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPulmonary abnormalities, such as interstitial lung disease, have been relatively well studied in patients with systemic lupus erythematosus (SLE). However, it remains unclear whether the risk of bronchiectasis and its associated disease burden are increased in SLE.
methodsUsing the Korean National Health Insurance Service dataset, we conducted a population-based matched cohort study involving adults aged ≥20 years diagnosed with SLE (SLE cohort) between 2002 and 2012 and a 1:4 age, sex and health insurance service-matched cohort (matched controls). Beginning 1 year after enrolment, participants were followed until the date of a bronchiectasis diagnosis, death or 31 December 2019, whichever came first.
resultsDuring a median follow-up of 12.8 years (IQR 10.0-16.0 years), the incidence rate of bronchiectasis was higher in the SLE cohort than in the matched controls (374.8 vs 236.2/100 000 person-years, p<0.001). The SLE cohort showed a 1.46-fold (95% CI 1.22 to 1.76) increased risk of developing bronchiectasis compared with the matched cohort. Within the SLE cohort, age older than 40 years (highest adjusted HR (aHR) in those ≥70 years 25.08, 95% CI 7.62 to 82.53) and asthma (aHR 1.73, 95% CI 1.11 to 2.70) were associated with an increased risk of bronchiectasis. In contrast, obesity was inversely associated with the risk of bronchiectasis (aHR 0.56, 95% CI 0.38 to 0.82). Individuals with SLE who developed bronchiectasis had significantly higher rates of mortality, emergency department visits and hospitalisations than those who did not develop bronchiectasis.
conclusionsThe risk of bronchiectasis was higher in individuals with SLE than in controls, and its development was associated with a worse disease course, higher mortality during follow-up and increased healthcare utilisation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.